Navigation Links
IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Date:1/25/2008

provides the Company a pathway to a potential positive opinion from the CHMP," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We are encouraged by CHMP's preliminary consideration and look forward to completing the review process successfully with the goal of bringing this important treatment to the European market."

L-MTP-PE U.S. Regulatory Status

As previously announced, in the U.S. the Company continues to work with external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by the Children's Oncology Group (COG) and to respond to other questions in the not approvable letter the Company received from the U.S. Food and Drug Administration (FDA).

The COG is assisting the Company in collecting this patient follow up data and the Company anticipates it will likely take until the second half of 2008 to prepare the amendment to the New Drug Application (NDA) for L-MTP-PE.

About Osteosarcoma

About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemother
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Leukemia & Lymphoma Society (LLS) is taking an aggressive ... patients with cancers that remain stubbornly resistant to treatment. ... will continue to accept applications from the world,s best ... of blood cancer, and award grants based on merit. ...
... Pacira Pharmaceuticals, Inc. , an ... Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for ... the U.S. Food and Drug Administration (FDA). Pacira submitted ... indication of postsurgical analgesia by local administration. The FDA ...
Cached Medicine Technology:The Leukemia & Lymphoma Society Targets Research in Four Critical Areas of Unmet Medical Need 2
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... may improve the oral health of elderly and special-needs ... and Western University of Health Sciences. Standard oral ... or impossible for patients with mental challenges or impaired ... xerostomia, or dry mouth, the lack of saliva reduces ...
... today the completion of the Phase I BCG clinical trial ... all safety reports to the U.S. Food and Drug Administration ... the Phase II clinical study, which will continue the investigation ... with existing type 1 diabetes, are actively underway. "We ...
... June 28, 2010 In the first ever published estimate ... with their minor children, a team led by a Wake ... cancer survivors are parenting young children, highlighting a group of ... in Cancer , a peer-reviewed journal of the American ...
... at the University of Leicester is set to play a ... autopsies, which many families find to be unpleasant. The ... Pathology Unit has won a substantive award by the National ... use of cardiac angiography in relation to near virtual autopsies. ...
... The first worldwide study of the societal impact of ... among those women who suffer from the condition, a ... Society of Human Reproduction and Embryology today (Monday). Dr. ... of Oxford, UK, said that the results of this ...
... leading scientific and health policy organizations today launched a ... www.viennadeclaration.com ), a statement seeking to improve community health ... evidence into illicit drug policies. Among those supporting the ... Laureate and International AIDS Society (IAS) Governing Council member ...
Cached Medicine News:Health News:Tray bleaching may improve oral health of elderly, special-needs patients 2Health News:Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial 2Health News:More than a million parents with minor children are cancer survivors 2Health News:Endometriosis has a significant effect on women's work productivity, first 2Health News:Endometriosis has a significant effect on women's work productivity, first 3Health News:The Vienna Declaration: A global call to action for science-based drug policy 2Health News:The Vienna Declaration: A global call to action for science-based drug policy 3Health News:The Vienna Declaration: A global call to action for science-based drug policy 4
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... pachymeter, with large high resolution LCD touch ... 300P is a portable, digital pachymeter which ... of a high frequency, low noise probe ... immediately upon application of the probe along ...
... pachymeter, with compact LCD screen and optional ... portable, weighing slightly more than 2 lbs ... large liquid crystal display. The combination of ... fast precise algorithm enables measurement immediately upon ...
... mounted on a stick to make ... are 37 mm square. They are ... 50PD. Plus red square. Now shipping ... prism on stainless steel stick. Specify ...
Medicine Products: